12:03 PM EST - Correvio Pharma Corp. : Announced that the U.S. Food and Drug Administration (FDA) will hold a Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting in connection with its review of the pending New Drug Application (NDA) for Brinaves (vernakalant hydrochloride, IV). The meeting will be held on December 10. Correvio Pharma Corp.
shares T.CORV are trading up $0.15 at $2.78.
